SCYX - speculative catalyst playSCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Disclaimer: This is not financial advice.
Upcoming Event: Preclinical Data Release on 04/24/2024
This is a highly speculative investment opportunity.
Recent News Highlights:
SCYNEXIS has been reaffirmed a 'Buy' rating due to strong financials and promising pipeline prospects.
The 'Buy' rating was also reaffirmed based on the success of Ibrexafungerp and a strong partnership with GSK.
Key Price Levels to Watch:
Monitor the resistance levels at $1.70, $1.85, and $2.00. Breaking these levels could indicate a potential upward movement. Consider taking partial profits at these levels to secure gains.
Stop Loss (SL): Set below $1.30 to minimize risk.
Take Profit (TP): Target approximately $2.15.
Additional information can be found in the accompanying chart.
Please trade with caution.
